Skip to main content
Apeloa Pharmaceutical Co.,Ltd. logo

Apeloa Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 000739 ISIN · CNE000000Q45 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,841 across all filing types
Latest filing 2025-08-29 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 000739

About Apeloa Pharmaceutical Co.,Ltd.

https://www.apeloa.com

Apeloa Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and distribution of active pharmaceutical ingredients (APIs), intermediates, and finished dosage forms. The company operates three core business pillars: API production, Contract Development and Manufacturing Organization (CDMO) services, and finished drug products. Its therapeutic focus includes cardiovascular, anti-infective, anti-viral, and oncology treatments. Apeloa utilizes an integrated supply chain to deliver chemical and biological solutions to a global client base. The organization maintains compliance with international quality standards, including certifications from the FDA, EMA, and PMDA. Its CDMO services encompass the full product lifecycle, from process chemistry and analytical development to large-scale commercial manufacturing, supported by specialized technology platforms such as continuous flow chemistry and enzymatic synthesis.

Recent filings

Filing Released Lang Actions
关于对下属公司担保的进展公告
Regulatory Filings Classification · 95% confidence The document is an announcement from 普洛药业股份有限公司 regarding the progress of guarantees provided to its subsidiaries. It details specific guarantee contracts, amounts, terms, and the financial status of the guaranteed subsidiaries. The document includes board approval information and cumulative guarantee amounts. It is a regulatory announcement about financing guarantees rather than a financial report, earnings release, or management discussion. The document length is 3529 characters, relatively short, and it does not contain comprehensive financial statements or detailed financial analysis. It is not a report itself but an announcement of guarantee progress and related board opinions. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-08-29 Chinese
2025年中期利润分配方案
Notice of Dividend Amount Classification · 100% confidence The document is a formal announcement from 普洛药业股份有限公司 regarding the 2025 mid-year profit distribution plan. It details the dividend payout, the basis for calculation, and references board and audit committee approvals. The document is relatively short (2080 characters) and focuses on the dividend distribution scheme rather than presenting full financial statements or comprehensive financial performance data. It also includes references to relevant laws and regulations and mentions the approval process. This type of document is a Notice of Dividend Amount, as it announces the dividend amount, payment basis, and related details to shareholders. It is not an Annual Report, Interim Report, or Earnings Release, nor is it a proxy solicitation or management report. Therefore, the correct classification is Notice of Dividend Amount (DIV).
2025-08-19 Chinese
信息披露事务管理制度
Governance Information Classification · 95% confidence The document is a detailed internal policy document titled "Information Disclosure Management System" for a company, outlining rules, responsibilities, and procedures related to information disclosure, including periodic reports, temporary reports, confidentiality, and internal controls. It references regulatory requirements from the China Securities Regulatory Commission and Shenzhen Stock Exchange, and covers the preparation and disclosure of annual, semi-annual, and quarterly reports, but it is not itself a financial report or an announcement of financial results. It is a governance and compliance document detailing the company's internal rules and governance practices related to information disclosure. Therefore, it fits best under Governance Information (CGR). The document length and content confirm it is not a brief announcement or a report publication announcement, nor a financial report or earnings release.
2025-08-19 Chinese
委托理财管理制度
Governance Information Classification · 95% confidence The document is titled '委托理财管理制度' which translates to 'Entrusted Financial Management System' or 'Delegated Financial Management Policy' of 普洛药业股份有限公司 (Puluo Pharmaceutical Co., Ltd.). It outlines internal policies, principles, decision-making authority, risk control, and information disclosure related to the company's entrusted financial management activities. There are no financial statements, earnings data, or audit results presented. The document is a governance or internal control policy document rather than a financial report or announcement. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Capital Update. It is not a regulatory filing or announcement of a report but a detailed internal governance document. Therefore, the best fitting category is Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices. The document length is 3634 characters, which is substantive and not a brief announcement. Confidence is high due to the clear nature of the document as a governance policy.
2025-08-19 Chinese
投资者关系管理制度
Governance Information Classification · 95% confidence The document is titled '投资者关系管理制度' which translates to 'Investor Relations Management System'. It outlines the principles, objectives, content, methods, departmental responsibilities, and rules for managing investor relations within the company. There are no financial statements, earnings data, or regulatory filings such as annual or quarterly reports. The document is a policy or governance document related to investor relations management and corporate governance practices. It is not a report, announcement, or transcript. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices. The document length is 4136 characters, which is consistent with a detailed governance policy document rather than a brief announcement or a full financial report.
2025-08-19 Chinese
控股子公司管理制度
Governance Information Classification · 95% confidence The document is titled '控股子公司管理制度' which translates to 'Management System for Controlling Subsidiaries' of a company. It contains detailed internal governance rules, management structures, responsibilities of directors and senior management, financial management, audit supervision, and procedures for major decisions within subsidiaries. There is no indication that this is a financial report, earnings release, or regulatory filing. It is a governance document outlining internal rules and management practices. Therefore, it fits best under Governance Information (CGR). The document length is 4451 characters, which is sufficient for a detailed governance report rather than a brief announcement or certification.
2025-08-19 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.